Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons resulting in progressive paralysis and respiratory failure. About 1 in every 400 people dies of ALS, usually within 3 to 5 years of symptom onset. The lack of effective therapy means that although the incidence is comparable to that of multiple sclerosis, the prevalence is low. The causes of ALS are largely unknown, but the only disease-modifying therapy, riluzole, was designed based on one hypothesis of disease causation, the excitotoxic hypothesis. In this paper we will review current ideas about the causes of ALS and the therapeutic opportunities they suggest.
CNS & Neurological Disorders - Drug Targets
Title: Molecular Insights and Therapeutic Targets in Amyotrophic Lateral Sclerosis
Volume: 7 Issue: 1
Author(s): Ammar Al-Chalabi and Vineeta B. Tripathi
Affiliation:
Abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons resulting in progressive paralysis and respiratory failure. About 1 in every 400 people dies of ALS, usually within 3 to 5 years of symptom onset. The lack of effective therapy means that although the incidence is comparable to that of multiple sclerosis, the prevalence is low. The causes of ALS are largely unknown, but the only disease-modifying therapy, riluzole, was designed based on one hypothesis of disease causation, the excitotoxic hypothesis. In this paper we will review current ideas about the causes of ALS and the therapeutic opportunities they suggest.
Export Options
About this article
Cite this article as:
Al-Chalabi Ammar and Tripathi B. Vineeta, Molecular Insights and Therapeutic Targets in Amyotrophic Lateral Sclerosis, CNS & Neurological Disorders - Drug Targets 2008; 7 (1) . https://dx.doi.org/10.2174/187152708783885110
DOI https://dx.doi.org/10.2174/187152708783885110 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Current Topics in Medicinal Chemistry Molecular Biomarkers for Amyotrophic Lateral Sclerosis
Current Bioinformatics Drosophila melanogaster in the Study of Human Neurodegeneration
CNS & Neurological Disorders - Drug Targets Recent Progress in Anticonvulsant Drug Research: Strategies for Anticonvulsant Drug Development and Applications of Antiepileptic Drugs for Non-Epileptic Central Nervous System Disorders
Current Topics in Medicinal Chemistry PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Current Alzheimer Research Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
Current Medicinal Chemistry Current Pathogenesis of Alzheimer’s Disease and Plants Derived Neuroprotective Phytoconstituents: A Comprehensive Review
Current Psychopharmacology Neurotransmitters and Microglial-Mediated Neuroinflammation
Current Protein & Peptide Science Molecular Genetics and Biomarkers of Polyglutamine Diseases
Current Molecular Medicine MAPKs as Mediators of Cell Fate Determination: an Approach to Neurodegenerative Diseases
Current Medicinal Chemistry GSTP1 Polymorphisms and their Association with Glutathione Transferase and Peroxidase Activities in Patients with Motor Neuron Disease
CNS & Neurological Disorders - Drug Targets Minocycline and Cytoprotection: Shedding New Light on a Shadowy Controversy
Current Drug Delivery Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Biomarkers for Alzheimer’s Disease
Current Alzheimer Research Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Current Pharmaceutical Design Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases
Protein & Peptide Letters Clinical Applications of Myostatin Inhibitors for Neuromuscular Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Mechanisms in Aging and Current Strategies to Counteract Sarcopenia
Current Aging Science